PLoS ONE (Jan 2021)

Willingness to participate in COVID-19 vaccine trials; a survey among a population of healthcare workers in Uganda.

  • Jonathan Kitonsa,
  • Onesmus Kamacooko,
  • Ubaldo Mushabe Bahemuka,
  • Freddie Kibengo,
  • Ayoub Kakande,
  • Anne Wajja,
  • Vincent Basajja,
  • Alfred Lumala,
  • Edward Ssemwanga,
  • Robert Asaba,
  • Joseph Mugisha,
  • Benjamin F Pierce,
  • Robin Shattock,
  • Pontiano Kaleebu,
  • Eugene Ruzagira

DOI
https://doi.org/10.1371/journal.pone.0251992
Journal volume & issue
Vol. 16, no. 5
p. e0251992

Abstract

Read online

BackgroundHealthcare workers (HCWs) are at high risk of acquiring SARS-CoV-2 and COVID-19 and may therefore be a suitable population for COVID-19 vaccine trials. We conducted a survey to evaluate willingness-to-participate in COVID-19 vaccine trials in a population of HCWs at three hospitals in Uganda.MethodsThe survey was conducted between September and November 2020. Using a standardised questionnaire, data were collected on socio-demographics, previous participation in health research, COVID-19 information sources, underlying health conditions, and willingness-to-participate in COVID-19 vaccine trials. Data were analysed descriptively and a binomial generalised linear model with a log link function used to investigate factors associated with unwillingness to participate.Results657 HCWs (female, 63%) were enrolled with a mean age of 33 years (Standard Deviation, 10). Overall willingness-to-participate was 70.2%. Key motivating factors for participation were: hope of being protected against COVID-19 (81.1%), altruism (73.3%), and the opportunity to get health care (26.0%). Selected hypothetical trial attributes reduced willingness-to-participate as follows: weekly-quarterly study visits over a 12-month period (70.2%-63.2%, P = 0.026); provision of approximately 50ml of blood at each study visit (70.2%-63.2%, P = 0.026); risk of mild-moderate local adverse reactions (70.2%-60.3%, PConclusionsWillingness-to-participate in COVID-19 vaccine trials among HCWs in Uganda is high but may be affected by vaccine trial requirements and concerns about the safety of candidate vaccines.